申请人:Clementia Pharmaceuticals Inc.
公开号:US10980778B2
公开(公告)日:2021-04-20
The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.
本发明的特点是通过向多发性骨软骨瘤(MO)患者施用帕罗伐汀(又称 R667)或其药学上可接受的盐,抑制骨软骨瘤的形成、减小其大小并减缓其生长。本文所述的方法还可以改善与MO患者骨软骨瘤形成和生长相关的并发症。